Background
==========

DNA methylation, the most important and common part of epigenetic, regulates gene expression by modified DNA without the changing of the genomic sequence. DNA methylation is a process in which a methyl group is covalently bound to a 5-position of cytosine in the context of a cytosine-guanine dinucleotide (CpG) in the mammalian genome \[[@B1]\]. Methylation of CpG-rich promoters is used by mammals to prevent transcriptional initiation, to ensure the inactivation of X chromosome and the silence of imprinted genes and parasitic DNAs. Recent studies show that methylation also affects the stability and structure of chromosomes. And the abnormal hypomethylation can cause many human diseases including many kinds of cancer \[[@B2],[@B3]\]. However, the potential roles of methylation in tissue-specific gene expression and in the regulation of CpG-poor promoters are less well established \[[@B4]\]. On the other hand, Xiang H et al. estimate that more than 0.11% of genomic cytosines are methylcytosines, all of which probably occur in CG dinucleotides. CG methylation is substantially enriched in gene bodies and positively correlated with gene expression levels, suggesting it has a positive role in gene transcription \[[@B5]\].

Recently, researchers have conducted extensive research on the mechanism of DNA methylation and its role in embryonic development. DNA methylation has been demonstrated to be required for vertebrate early embryogenesis and can regulate temporal and spatial expression of genes controlling cell fate and differentiation which is a complicated and predetermined developmental program. Moreover, DNA methylation provides necessary direction for the multitude of changes that are required to proceed from a fertilized oocyte to a fully developed adult animal \[[@B6],[@B7]\]. Sperm and eggs carry distinctive epigenetic modifications that are adjusted by reprogramming after fertilization. The paternal genome in a zygote undergoes active DNA demethylation before the first mitosis \[[@B8]\]. During the early phases of mammalian development, DNA methylation is extensively reprogrammed \[[@B9]\]. The maintenance of DNA methylation and normal methylation level is necessary for normal embryonic development and tissue-specific differentiation. The changes of DNA methylation will result in abnormal expression of gene and produce various phenotypes such as pregnancy failure, congenital defects and acquired diseases. For the design of targeted therapies to abnormal DNA methylation, there is important theoretical and clinical significance to studying and understanding the status of DNA methylation in the development of embryo.

Methylated Microarray analysis is efficient technology platform for looking for epigenetic methylation markers. With the completion of many whole-genome sequences, new types of genome-wide experiments are possible. Tiling Arrays offer a physical readout of a genome and can be used as a discovery tool for mapping sites of DNA interaction in chromatin immunoprecipitation (ChIP) experiments, understanding global epigenomic changes like methylation. Currently, most studies use various animal models to study the methylation status during embryonic development. In this study, GeneChip® Human Tiling 2.0R Array set is used to look for methylation markers in amniotic fluid samples in an early development of human embryo. Moreover, clone sequencing is used to test and verify the results of Methylated Microarray analysis. And Real-time quantitative PCR (RTQ-PCR) is used to verify the function of hypermethylation and hypomethylation in the identified genomic regions.

Methods
=======

Study samples
-------------

Eight women with 18--24 weeks of euploid pregnancies admitted to Prenatal Diagnosis Center of Henan Provincial People' hospital between March 2013 and May 2013 were recruited. 10 ml maternal peripheral blood and 20 ml amniotic fluid were collected from the 8 participants. All samples were frozen at -80°C before analysis. The pregnant information about the participants was shown in Table [1](#T1){ref-type="table"}. All the participants were not complicated with any diseases and provided their written informed consent for the collection of the samples and subsequent analysis. The investigation was conducted in accordance with humane and ethical research principles of Henan Provincial People' hospital, China. This study was approved by the Ethics Committee of Henan Provincial People's Hospital, China.

###### 

General information about the participants

   **Sample ID**   **Maternal age (years)**   **Reproductive history**   **Pregnant week**   **Fetal sex**
  --------------- -------------------------- -------------------------- ------------------- ---------------
       p356                   28                        G1P0                  18 week            46,XX
       p357                   37                        G2P0              19 week + 3 day        46,XX
       p358                   33                        G1P0                  20 week            46,XX
       p359                   24                        G3P0              19 week + 6 day        46,XY
       p360                   32                        G4P1                  22 week            46,XY
       p362                   27                        G1P0              21 week + 5 day        46,XX
       p363                   38                        G3P1              20 week + 5 day        46,XX
       p364                   30                        G2P1              24 week + 2 day        46,XX

Exclusion of maternal DNA
-------------------------

The fifteen autosomal STR loci and a Amelogenin locus are amplified to determine whether there is maternal DNA in fetus amniotic fluid by using the PowerPlex® 16 system kit in a multiplex amplification reaction system following manufacturer's instructions using 25 μl reactions containing 1.0 μl (0.5-2 ng) genomic DNA, 5.0 μl PowerPlex® 16 5 × Master Mix, 5.0 μl PowerPlex® 16 5 × Primer Pair Mix and 14.0 μl ddH~2~O. Thermal cycling was performed using the GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA, USA). Temperature cycling conditions for PCR reactions are as follows: denaturation for 11 min at 95°C, and then 1 min at 96°C, followed by 10 cycles for 30 s at 94°C, 30 s at 60°C, 45 s at 70°C, then 20 cycles for 30 s at 90°C, 30 s at 60°C, 45 s at 70°C and a final elongation step at 60°C for 30 min.

The PCR products have been separated and detected by capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 2 μl PCR product or Allelic Ladder has been mixed with 15 μl Hi-Di formamide and 0.5 μL internal lane standard ILS 600 (Promega, WI, USA). The loading mixture has been denatured at 95°C for 3 min, followed by chilling on ice for 3 min immediately. STR alleles have been analyzed by comparison with kit allelic ladders using the GeneMapper ID 3.2 software (Applied Biosystems, Foster City, CA, USA). Control DNA from cell line 9947A (Promega, Madison, WI, USA) has been genotyped as standard reference in all experiments.

Methylated DNA capture
----------------------

Methylamp™ Methylated DNA Capture kit (Epigentek Group Incorporation, Farmingdale, New York, USA) has been used to enrich and capture methylated DNA fragments from blood and amniotic fluid samples for use in gene-specific DNA methylation studies on a genome wide scale. According to the manufacturer's protocol of the kit, Methylated DNA Capture include the following steps: i) DNA isolation, ii) breaking DNA as fragments by sonicator: sonication for 10 s, and pause 30 s, repeat it 15 times at 100 W, check the DNA size by running 1.2% agarose gel, iii) incubating sonicated/digested DNA at 98°C for 3 min and immediately put on ice, iv) bisulfite conversion and methylated DNA immunoprecipitation, v) release of mDNA from antibody complex, vi) capturing of mDNA, vii) elution of mDNA. Following methylated DNA immunoprecipitation (meDIP) processed, the methlation of the DNA can be analyzed using meDIP-ChIP.

DNA methylation analysis
------------------------

GeneChip® Human Tiling 2.0R Array set (Affymetrix Incorporation, Santa Clara, CA, USA) has been used for analysis of methylated DNA in a whole-genome wide. GeneChip® Fluidics Station 400 and GeneChip® Scanner 3000 7G (Affymetrix Incorporation, Santa Clara, CA, USA) are needed for analysis. According to the Affymetrix chip-on-chip procedures we first amplified immunoprecipitated DNA targets using the following cycle conditions: 14 cycles for 30 s at 95°C, 30 s at 45°C, 30 s at 55°C, 1 min at 72°C, then 14 cycles for 30 s at 95°C, 30 s at 45°C, 30 s at 55°C (for every subsequent cycle add 5 second), 1 min at 72°C, and 4°C for ever. Secondly, we purified the PCR products using MiniElute PCR purification kit (Qiagen Incorporation, Valencia, CA, Spain) and got fragmentation mix, then put up fragmentation mix for Tiling array, following this step we used GeneChip® WT Double-Stranded DNA Terminal Labeling Kit (Affymetrix Incorporation, Santa Clara, CA, USA) to label fragmented Double-Stranded DNA, and used GeneChip® Hybridization, Wash, and Stain Kit (Affymetrix Incorporation, Santa Clara, CA, USA) to hybridize, wash and stain the labeled target DNA according to the procedure of the kit. Finally, we scan the barcode on the chip using appropriate protocol.

Clone sequencing
----------------

Clone sequencing strategy has been used to verify the selected methylation markers by microarray analysis method in a whole-genome wide (Sangon Biotech Incorporation, Shanghai, China). Before the clone sequencing was conducted, bisulfite conversion of the sample genomic DNA was done by using EpiTect Bisulfite kit (Qiagen Incorporation, Valencia, CA, Spain) according to the manufacturer's procedure. Nine fetus hypermethylation markers and twelve fetus hypomethylation markers were tested. The primer sequences were shown in Table [2](#T2){ref-type="table"}.

###### 

The primers for clone sequencing

   **Primer name**  **Forward primer**               **Reverse primer**                **Amplicon size (bp)**
  ----------------- -------------------------------- -------------------------------- ------------------------
         FH1        GGAGTTTTTTATGTATTTGGTATTT        CATACCCCCAAAAAATAAAATTTAAAATCT             383
         FH2        ATGGGGAAGTAGATTTGGGTAT           TCACTTTAACTACCCCCAAATATTATAA               456
         FH3        TAGGGGTGTTATGAAGGTGGTA           ATTCTATATAATCACTTCCACATTCTTAAT             418
         FH4        AGGGTTGGGTAATATTTTTATTGTTATAAT   ACAAACCAAATTACCCCCATT                      492
         FH5        ATGGGAGGTGGGTTTTGTT              AAAATCACCTACCAACCTCAATAACTA                446
         FH6        GGTTTTTTAGATTTGGATGTGATTTAGG     CCCCCCCATAAATAAAACCTT                      470
         FH7        GTGGAGATAGTAGTGAGTAGAGA          AATCCCATATAAACCCAAACCT                     484
         FH8        TTTTTTTTGTAGTTTAGGGTTTTTTGTAT    CTCTTCTAAAACATCCACCTTACA                   391
         FH9        TGAGAAATTTAAGGAGTGTGTGT          TACCCCCATCTATCCTATACTCT                    452
         FL1        GGGAGGAAGGAGTTGGTAGGTTTTTAT      ACTACCCAAATCTCTCACTTTACAATAAC              357
         FL2        GTTTTTAGTTAAGTTTTTTGGGGAGAGG     AACAACTAATTTCACACCATATCTTAT                349
         FL3        TGGGAAGTATGTGGAAGTGGA            CACCCCCCATTTTAAAAACAACAATCTAT              290
         FL4        GGAAATGTGTTAAGGTAAGAGGTTATAAG    CCAAAACTTCTACCCCTAAAAAT                    452
         FL5        TTTTGTTAAGAATAATAAGAGAGGGTAAGT   ATCTATAAATCTTTTTTCCAAACTCAC                481
         FL6        GGGTTTTTTGTTTAATTGTGTATTGGAG     ACCTAACCAAACCCCATACT                       388
         FL7        GGATTATTAGTTGTATAATTATGGAGATT    ACCCCCTCTCTACTACTAATATAA                   378
         FL8        AAGGGGATTTTTTTGGAAAGTAT          CATCTCAAACTCTCACCATCATAAATA                489
         FL9        GTGTTTAGTAATAGGTAGTTTGGAAAATT    CTTACTTACAATTCCAATACCTATAATCAC             435
        FL10        TGGTATTAGTGGGAGTTTAATAGATG       AACTCAAATAAACCCACATACACTATAAT              413
        FL11        TGGATTGATATAGGGAAAAAAAAGGAGAA    CACTCCCAAATCTCTACTAACCTCTA                 465
        FL12        GTGGGTTTTATTTAGGTTGTGAGTA        CTTAAACTCCTCTTCCCCAACAC                    350

FH indicates fetus hypermethylation DNA markers and FL indicates fetus hypomethylation DNA markers.

Real-time quantitative PCR
--------------------------

Real-time quantitative PCR was used to verify the function of hypermethylation and hypomethylation in the identified genomic regions. Total RNA was prepared from maternal peripheral blood and amniotic fluid samples (400 mg) using TRIzol® Reagent (Life Technologies Incorporation, CA, USA). Reverse transcription was carried out with the GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA, USA) in a reaction volume of 20 μl containing 5 μl of total RNA, 1 μl random Primers, 5 μl Rnase-free ddH~2~O, 4 μl Reaction Buffer 5×, 2 μL dNTP Mix(10 mmol/L), 20U ribonuclease inhibitor (Applied Biosystems, Foster City, CA, USA), and 20 U of reverse transcriptase (Life Technologies Incorporation, Ambion. CA, USA). Specific primers used to amplify the genes ERG, SH2D3C, EML3, TRIM71, HOXA3, HOXA11, and HOXA5 (showed in Table [3](#T3){ref-type="table"}) were designed using online software Primer 3 Version 0.4.0 (Whitehead Institute, USA), and the endogenous β-actin was employed as an internal standard. Sybr Green RTQ-PCR analysis were performed with LightCycler480 Software Setup (Roche Incorporation, Basel, Switzerland). RTQ-PCR was performed using the following cycle parameters: 3 minutes at 95°C, followed by 40 cycles of 15 sec at 95°C and 40s at 60°C. For each gene, RTQ-PCR was conducted in 20 μl reactions of 1 μl cDNA (5 ng), 10 μl Sybr Green qPCR Master Mix 2× (Applied Biosystems, Foster City, CA, USA), 1 μl of each primer (10 μM), 7 μl ddH~2~O. To ensure the quality of the measurements, both negative and positive controls were systematically included in duplicate in each plate.

###### 

The primers for real-time quantitative PCR

   **Primer name**  **Forward primer**         **Reverse primer**        **Amplicon size (bp)**
  ----------------- -------------------------- ------------------------ ------------------------
         ERG        TCCCCGTGACATCTTCCAGT       AGCCTCCGCCAGGTCTTTA                140
       SH2D3C       GGCTAAAGGAACTGTCAGAAAATG   CGGGTTGAAGGAAGAAGTGAC               95
        EML3        CTTCAACCCTCGTGACAGCA       ATTCCCAGGAACCCCTACTC                94
       TRIM71       CCACAGCTTCATCTACCTCCA      TTCTTATGCCTCGCCGTCA                195
        HOXA3       TTCCACTTCAACCGCTACCT       GTACTTCATGCGGCGATTCT               111
       HOXA11       GCCCAAGGTAGCCCAATAA        CTGGACCCGAGACGTAGTAAGT              94
        HOXA5       GCGAGCCACAAATCAAGCA        GGATAGCGACCGCAAAATG                 77

Statistical analysis
--------------------

Affymetrix® Tiling Analysis Software (TAS) was used for analysis and quality control of the GeneChip Tiling Arrays. TAS analyzed feature intensity data stored in GeneChip® Operating Software (GCOS), output cel files and produced signals and p-values for each genomic position interrogated. Affymetrix Power Tools Software 1.15.1 was used to convert cel files to text files. The methylation regions of fetus group and mother control group were compared by using Modle-based Analysis of Tiling-array (MAT) calculation (*p* \< 0.0001). CisGenome ver 2.0 Software (<http://www.biostat.jhsph.edu/~hji/cisgenome/>) was used for annotating the gene names which were close to methylation regions. Scatter plots were constructed utilizing R Software Packages 3.0.1. Two sets of results (the fetus and the mohter) of clone sequencing were analyzed by Quantification tool for Methylation Analysis (QUMA) and compared by statistical software SPSS Version 13.0 using Analysis of Variance (ANOVA) method (*p* \< 0.01). The statistical analysis of the RTQ-PCR results was done using ΔΔCt methods. Analysis of Variance (ANOVA) was also used for comparison the two sets of results of RTQ-PCR (*p* \< 0.01).

Results and discussion
======================

DNA Methylation is a crucial epigenetic modification involved in embryonic development, transcription, chromation structure, X chromosome inactivation, gene imprinting, chromosome stability and occurrence of different kinds of tumors \[[@B10]-[@B15]\]. In recent years, researchers have conducted extensive studies on the mechanism of DNA methylation and its role in embryonic development using different biological models, such as human and mouse cell lines, gene knockout mice, zebra fish and so on \[[@B6],[@B7],[@B16]-[@B18]\]. These studies all show that DNA methylation is important for regulating temporal and spatial expression of genes for controlling cell fate and differentiation. In some other studies, DNA methylation has been demonstrated to be required for vertebrate early embryogenesis \[[@B19]-[@B21]\]. Here we collect eight pairs of amniotic fluid and maternal blood samples for selecting the hypermethylation and hypomethylation DNA markers. The fetus and mother DNA samples are all amplified by using the PowerPlex® 16 system kit in a multiplex amplification reaction system and there is no maternal DNA in fetus amniotic fluid.

DNA methylation analysis of the 8 pairs amniotic fluid and maternal blood DNA samples are conducted by using GeneChip® Human Tiling 2.0R Array set. In this study, from the fetus and mother groups we have got the values of the DNA methylation levels for thousands of methylation markers respectively. In order to get fetus methylation markers which are significant different from that of mother in DNA methylation level, we have compared the values of the DNA methylation levels of the methylation markers of fetus with that of mother by using MAT calculation (*p* \< 0.0001). Scatter plots are constructed to show the results of the comparison using R Software Packages 3.0.1. Two of the Scatter plots were showed in Figure [1](#F1){ref-type="fig"}. As shown in Figure [1](#F1){ref-type="fig"}, red solid triangles which represent the DNA methylation level of fetus in this chromosomal location gathered together, blue open circles which represent the DNA methylation level of mother in this chromosomal location gathered together, and red solid triangle groups are separated from blue open circle groups. If the Scatter plots results are the same as Figure [1](#F1){ref-type="fig"}, we can determine that there must be significant different in DNA methylation level from that of fetus and mother. According to the above principle we select 59 fetus hypermethylation DNA markers and 56 fetus hypomethylation DNA markers which all show significant differences between fetus and mothers. To further understand the sequence structure and function of the 59 fetus hypermethylation DNA markers and 56 fetus hypomethylation DNA markers, we check their associated genes where these markers locate in (<http://www.ncbi.nlm.nih.gov/>). We have finally identified 9 fetus hypermethylation DNA markers and 12 fetus hypomethylation DNA markers and their associated genes according to their function (showed in Table [4](#T4){ref-type="table"}).

![**The scatter plots generated by using R software packages based on the methylation degree. (A)** The fetus hypermethylation DNA marker (HOXA3) on chromosome 7; **(B)** The fetus hypomethylation DNA marker (FFAR2) on chromosome 19. \*Red solid triangle represent the DNA methylation level of fetus in this chromosomal location; Blue open circle represent the DNA methylation level of mother in this chromosomal location.](1755-8794-7-18-1){#F1}
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The information of the 9 fetus hypermethylation DNA markers (FH) and 12 fetus hypomethylation DNA markers (FL)

   **Marker ID**  **Chromosomal locition**       **Associated gene**
  --------------- ------------------------------ --------------------------------------------------------------------------------
        FH1       ChrM:1-542                     Mitochondrial DNA D-loop
        FH2       ChrM:16,025-16,571             Mitochondrial DNA D-loop
        FH3       Chr19:40,628,281-40,629,300    Free fatty acid receptor 2 (FFAR2)
        FH4       Chr21:38,791,600-38,792,000    Erythroblastosis virus E26 oncogene onmcogene homolog (ERG)
        FH5       Chr7:2,411,800-2,412,100       Carbohydrate (chondroitin 4) Sulfotransferase 12 (CHST12)
        FH6       Chr12:6,528,400-6,528,750      Intermediate filament family orphan 1 (IFFO1)
        FH7       Chr9:129,579,800-129,580,000   SH2 domain containing 3C (SH2D3C)
        FH8       Chr17:36,717,500-36,717,900    Keratin associated protein 16-1 (KRTAP16-1)
        FH9       Chr19:1,019,900-1,020,200      Histocompatibility (minor) HA-1 (HMHA1)
        FL1       Chr7:27,130,100-27,130,600     Homeobox A3 (HOXA3)
        FL2       Chr11:62127350-62127700        Echinoderm microtubule associated protein like 3 (EML3)
        FL3       Chr3:32,835,500-32,835,800     Tripartite motif containing 71, E3 ubiquitin protein ligase (TRIM71)
        FL4       Chr7:27,185,300-27,185,650     Homo sapiens homeobox A11 (HOXA11)
        FL5       Chr6:10,664,250-10,664,600     Homo sapiens glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (GCNT2)
        FL6       Chr7:27,113,100-27,113,300     Homo sapiens homeobox A2 (HOXA2)
        FL7       Chr7:27,148,050-27,148,400     Homeobox A5 (HOXA5)
        FL8       Chr19:12,997,300-12,997,450    Nuclear factor I/X (NFIX) (CCAAT-binding transcription factor)
        FL9       Chr8:116,753,900-116,754,200   Homo sapiens trichorhinophalangeal syndrome I (TRPS1)
       FL10       Chr5:95,321,600-95,321,800     Elongation factor, RNA polymerase II, 2 (ELL2)
       FL11       Chr7:32,213,400-32,213,600     Phosphodiesterase 1C, calmodulin-dependent (PDE1C)
       FL12       Chr8:82,066,300-82,066,500     Phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1)

To test and verify the 21 selected methylation DNA markers by microarray analysis method in a whole-genome wide, we used clone sequencing strategy. One of the clone sequencing results was shown in Figure [2](#F2){ref-type="fig"}. The results of clone sequencing were analyzed by Quantification tool for Methylation Analysis (QUMA) and compared by statistical software SPSS Version 13.0 using Analysis of Variance (ANOVA) method (*p* \< 0.01). According to the results of ANOVA, we finally selected 7 methylation DNA markers from the 21 according to the results of the clone sequencing. They are FH4 (Chr21:38,791,600-38,792,000), FH7 (Chr9:129,579,800-129,580,000), FL1 (Chr7:27,130,100-27,130,600), FL2 (Chr11:62,127,350-62,127,700), FL3 (Chr3:32,835,500-32,835,800), FL4 (Chr7:27,185,300-27,185,650) and FL7 (Chr7:27,148,050-27,148,400).

![**The clone sequencing result of methylation DNA marker located on chromosome 21:38791600--38792000.** The DNA Marker is a fetus hypermethylation DNA marker and related with Erythroblastosis virus E26 oncogene onmcogene homolog (ERG) gene. **(A)** The clone sequencing result of the mother, **(B)** The clone sequencing result of the fetus \*X axis represents different methylation sites; Y axis represents different clones. \*black circle represent methylation sites; white circle represent unmethylated sites.](1755-8794-7-18-2){#F2}

If these 7 genes are really regulated by specific methylation status in the fetus, the mRNA expression of ERG and SH2D3C should be lower in the amniotic fluid, whereas those of EML3, TRIM71, HOXA3, HOXA5, and HOXA11 are higher in the amniotic fluid than in the maternal peripheral blood cells. To verify the function of the 7 genes, we did the real-time quantitative PCR (RTQ-PCR) comparison between amniotic fluid samples and maternal peripheral blood cells on these 7 genes. The results of the RTQ-PCR were consistent with the clone sequencing results. However, Analysis of Variance (ANOVA) showed that only SH2D3C was reduced by 0.47 ± 0.33 folds (*p* \< 0.01) in the amniotic fluid, and EML3, TRIM71, HOXA3, and HOXA5 were enhanced by 1.31 ± 0.72, 2.57 ± 1.37, 13.07 ± 9.45 and 2.38 ± 2.69 folds (*p* \< 0.01) respectively in the amniotic fluid than in the maternal peripheral blood cells. In order to clarify whether the differences between mother and fetus were due to fetus gender differences, the experimental data were grouped according to fetus gender. The Analysis of Variance (ANOVA) results showed that there were no significant differences between male and female fetuses in methylation status. So we conclude that the differences in methylation status between mother and fetus have nothing to do with gender differences in our study.

Marker FH7 was associated with SH2D3C gene which encoded an adaptor protein and was a member of cytoplasmic protein family involved in cell migration. Until now, Research on the function of SH2D3C gene was still very rare. Marker FL2 was associated with EML3 gene which was a nuclear microtubule-binding protein required for the correct alignment of chromosomes in metaphase \[[@B22]\]. Marker FL3 was associated with TRIM71 gene which cooperated with microRNAs to repress Cdkn1a expression and promote embryonic stem cell proliferation \[[@B23],[@B24]\]. HOX genes called homeobox genes encoded the class of transcription factors were found in clusters A, B, C, and D on four separate chromosomes. The expression of these genes was spatially and temporally regulated during embryonic development. Marker FL1 was associated with HOXA3 gene which was a member of HOX gene family and was part of the A cluster on chromosome 7. It encoded a DNA-binding transcription factor which may regulate gene expression, morphogenesis and differentiation. Marker FL7 was associated with HOXA5 gene which also encoded the class of transcription factors. As HOXA3, the expression of this gene was spatially and temporally regulated during embryonic development. Methylation of this gene may result in the loss of its expression. Since the encoded protein up-regulates the tumor suppressor p53, this protein may play an important role in tumorigenesis. The previous studies showed HOX genes were involved in stem cell differentiation \[[@B25]\]. High-density association study of the HOX gene for volumetric BMD at the femoral neck and lumbar spine among older men was conducted and proved that HOXA gene regions were associated with both femoral neck and lumbar spine BMD \[[@B26]\]. However, HOX genes has not been given enough attention that they can regulate gene expression, morphogenesis, and differentiation and were involved in the regulation of uterine development and required for female fertility.

Conclusions
===========

In this study, we found 1 fetus hypermethylation DNA markers and 4 fetus hypomethylation DNA markers which all associated with the critical genes for fetus growth and development. Our results may provide valuable information for future research of fetus growth and development, and even can give some inspiration of the studies of the pathological pregnancy, such as Unexplained Recurrent Spontaneous Abortion (URSA) and early pregnant failure which generally occur at about 20 weeks in the embryonic development \[[@B27]\].
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